No Data
No Data
Boji medical technology (300404.SZ): Not currently involved in DRG/DIP fields.
On July 29, Gelunhui reported that Boji Medical Technology (300404.SZ) stated on the investor interaction platform that the company is a professional CRO service provider mainly providing pharmaceutical outsourcing services to pharmaceutical companies and does not currently involve DRG/DIP fields.
A-share Lightning protection on July 15 | Tailin Bio: Gao De Investment intends to reduce its shareholding by no more than 1.67%; Chipbond Technology: expects to lose 0.439 billion yuan in the first half of the year.
Boji Medical Technology's controlling shareholder, the concerted action person, intends to reduce its shareholding by no more than 1.5%. Tailin Bio's shareholder, Gaode Investment, intends to reduce its shareholding by no more than 1.67%. Xilinx expects to lose 0.439 billion yuan in the first half of the year. Greentown Technology stated that the U.S. Commerce Department has initiated an anti-dumping and countervailing investigation into certain low-speed vehicles imported from China.
Boji Medical Technology (300404.SZ): Received government subsidies of 2.89 million yuan.
Boji Medical Technology (stock code 300404) announced on July 3 that its wholly-owned subsidiary, Shenzhen Brightgene Bio-Medical Technology Co., Ltd., has received government subsidy funds related to revenue of 2,890,000.00 yuan recently, accounting for 11.87% of the net income attributable to shareholders of the listed company in the last audited accounting year.
As Boji Medical TechnologyLtd (SZSE:300404) Jumps 16% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth
Top Buy and Sell Ranking |
Today's top three net buy-in on the Dragon and Tiger List are Boji Medical Technology, Zhonglun New Materials, and Chuanzhi Education.
Boji Medical Technology rose by the daily limit of 20cm on the stock market, with Foshan Group buying a net of 66.4064 million yuan.
Boji medical technology (300404.SZ) rose by 20 cm today with a turnover of 477 million yuan and a turnover ratio of 21.18%. Dragon and Tiger List data shows that the 'Foshan faction' of fund investors ranks first in buying, with a net purchase of 66.4064 million yuan; the 'leisure and entertainment faction' ranks third in buying, with a net purchase of 15.7825 million yuan; and the 'low position mining faction' ranks fourth in buying, with a net purchase of 11.9872 million yuan. The net buying of the listed seats was 92.8867 million yuan throughout the day.
No Data